REHOVOT, Israel, February 15, 2022 /PRNewswire/ — Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize the development of life science products across multiple market segments, today announced that it will report financial results for the full year and fourth quarter 2021 on Thursday, March 10, 2022.
Announcement of financial results and earnings
On the day of the announcement, the Company’s management will hold a conference call to discuss the results to 9:00 a.m. Eastern Time4:00 p.m. Israel time. To access the conference call, please dial +1-888-281-1167 toll free from United States, or +972-3-918-0609 internationally. Access to the call will also be available via live webcast on the Company’s website at www.evogene.com.
A replay of the conference call will be available approximately two hours after the call ends. To access the replay, please dial +1-888-326-9310 toll free. United States, or +972-3-925-5901 internationally. The replay will be accessible via March 11, 2022and an archive of the webcast will be available at the webcast link for the following twelve months.
About Evogene Ltd. :
Evogene (NASDAQ: EVGN, TASE: EVGN) is a computational biology company that aims to revolutionize life science-based product development by using advanced technologies to increase the likelihood of success while reducing time and expense. development costs. We have established three unique technology engines, MicroBoost AI, ChemPass AI and GeneRator AI, leveraging big data and artificial intelligence and integrating a deep multidisciplinary understanding of life sciences. Each technology engine is focused on the discovery and development of products based on one of the following core components: microbes (Microboost AI), small molecules (ChemPass AI), and genetics (GeneRator AI). The company uses its technology engines to develop products through subsidiaries and with strategic partners. Currently, our main subsidiaries are using technology drivers to develop new products as follows: Human Microbiome Based Therapies by Biomica Ltd., Medical Cannabis by Canonic Ltd., Agricultural Chemicals by AgPlenus and Agricultural Biologics by Lavie Bio Ltd.
For more information, please visit: www.evogene.com.